Among the aforementioned therapeutic interventions, GLP-1R agonism alternatively seems to be an anti-obesity treatment, as GLP-1R agonists work as potent extrinsic appetite suppressants. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.